| Autor: |
Mansilla‐Polo, Miguel, Pons‐Benavent, Martí, Fernández‐Crehuet, Pablo, Vilarrasa, Eva, Albanell‐Fernández, Cristina, Morales‐Tedone, Enrico, Rausell‐Félix, Francisca, Alcalá‐García, Rebeca, Matellanes‐Palacios, María, Martín‐Ezquerra, Gemma, Alfageme, Fernando, Ciudad‐Blanco, Cristina, López‐Villaescusa, María Teresa, Garbayo‐Salmons, Patricia, Martorell, Antonio, Escutia‐Muñoz, Begoña, Navarro‐Blanco, Fernando, Martín‐Torregrosa, Daniel, Cuenca‐Barrales, Carlos, Molina‐Leyva, Alejandro |
| Předmět: |
|
| Zdroj: |
Australasian Journal of Dermatology; Nov2024, Vol. 65 Issue 7, pe198-e202, 5p |
| Abstrakt: |
In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient‐reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS‐PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well‐tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real‐world clinical practice for treating HS. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text